Vitamin K$_2$ Regulation of Bone Homeostasis Is Mediated by the Steroid and Xenobiotic Receptor SXR*

Michelle M. Tabb‡, Aixu Sun‡, Changcheng Zhou‡, Felix Grün‡, Jody Errandi‡, Kimberly Romero‡, Hang Pham‡, Satoshi Inoue§, Shyamali Mallick¶, Min Lin¶, Barry M. Forman§, and Bruce Blumberg‡¶

From the ‡Department of Developmental and Cell Biology, University of California, Irvine, California 92697-2300, the §Department of Geriatric Medicine, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan, and the ¶Division of Molecular Medicine, Gonda Diabetes Research Center, Beckman Research Institute, The City of Hope National Medical Center, Duarte, California 91010-3000

Vitamin K$_2$ is a critical nutrient required for blood clotting that also plays an important role in bone formation. Vitamin K$_2$ supplementation up-regulates the expression of bone markers, increases bone density in vivo, and is used clinically in the management of osteoporosis. The mechanism of vitamin K$_2$ action in bone formation was thought to involve its normal role as an essential cofactor for γ-carboxylation of bone matrix proteins. However, there is evidence that suggests vitamin K$_2$ also has a transcriptional regulatory function. Vitamin K$_2$ bound to and activated the orphan nuclear receptor SXR and induced expression of the SXR target gene, CYP3A4, identifying it as a bona fide SXR ligand. Vitamin K$_2$ treatment of osteosarcoma cells increased mRNA levels for the osteoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein. The known SXR activators rifampicin and hyperforin induced this panel of bone markers to an extent similar to vitamin K$_2$. Vitamin K$_2$ was able to induce bone markers in primary osteocytes isolated from wild-type murine calvaria but not in cells isolated from mice deficient in the SXR ortholog PXR. We infer that vitamin K$_2$ is a transcriptional regulator of bone-specific genes that acts through SXR to favor the expression of osteoblastic markers. Thus, SXR has a novel role as a mediator of bone homeostasis in addition to its role as a xenobiotic sensor. An important implication of this work is that a subset of SXR activators may function as effective therapeutic agents for the management of osteoporosis.

Osteoporosis is a common disease affecting the elderly, particularly postmenopausal women, although a significant minority of older men is also affected. It is defined as the gradual reduction in bone strength with advancing age that is manifested by such observations as bone fracture following minimal trauma (1–3). Several types of agents are used clinically in the United States to prevent or treat osteoporosis. These include estrogen/progestin replacement therapy, calcitonin, bisphosphonate, and selective estrogen receptor modulators (4). Vitamin K$_2$ was first reported to promote fracture healing in 1960 (5), and several studies showed that vitamin K$_2$ is closely associated with increased bone formation (6, 7) and decreased bone resorption (8–13). Low levels of dietary vitamin K are associated with increased risk of fractures (14–16). Accordingly vitamin K$_2$ is used clinically in Japan to treat osteoporosis either alone or in conjunction with 1α,25-(OH)$_2$ vitamin D$_3$ (17–20).

Vitamin K$_2$ is a family of naphthoquinones, the most biologically important of which is menatetrenone (for a review, see Ref. 21). Vitamin K$_2$ was discovered as a critical nutrient required for blood clotting. It acts as a cofactor for the microsomal γ-carboxylase that facilitates the post-translational conversion of glutamic acid to γ-carboxyglutamyl (Gla) residues (for a review, see Ref. 14). Post-translational conversion of 9–12 Gla to Gla residues is required for the function of proteins such as prothrombin and Factors VII, IX, and X in the blood clotting cascade (for reviews, see Refs. 21 and 22). In addition, Gla-containing proteins such as osteocalcin and matrix Gla protein are abundant in bone tissues where they are thought to play important roles in regulating mineralization (for reviews, see Refs. 23 and 24).

Recent studies have demonstrated that the orphan nuclear receptor SXR$^1$ (25) (also known as PXR (26), PAR (27), and NR1I2) plays a central role in the transcriptional regulation of xenobiotic detoxifying enzymes and transporters such as CYP3A4 and MDR1 (28–32). SXR is activated by a diverse array of pharmaceutical agents including Taxol, rifampicin, SR12813, clotrimazole, phenobarbital, hyperforin (33–35), the herbal antidepressant St. John’s wort (36), and peptide mimetic human immunodeficiency virus protease inhibitors such as ritonavir (28). These studies indicate that SXR functions as a xenobiotic sensor to coordinate regulation of drug clearance in the liver and intestine. Indeed gene knockout studies have confirmed a role for SXR in regulating the metabolism of en-

---

* This work was supported by National Cancer Institute Grant CA-87222, National Institutes of Health Grant GM-60572, and a gift from Eisai Co., Ltd. Japan. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed: Dept. of Developmental and Cell Biology, University of California, 5205 McGaugh Hall, Irvine, CA 92697-2300. Tel.: 949-824-8573; Fax: 949-824-4709; E-mail: blumberg@uci.edu.

1 The abbreviations used are: SXR, steroid and xenobiotic receptor; PXR, pregnane X receptor; CYP, cytochrome P-450; RT-PCR, reverse transcriptase PCR; QRT-PCR, quantitative real time RT-PCR; Rif, rifampicin; ALP, alkaline phosphatase; OCN, osteopontin; MGP, matrix Gla protein; OPG, osteoprotegerin; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; SRC-1, steroid receptor coactivator-1; ACT, activator of progestin and retinoid receptors; CHAPS, 3-[3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; F, forward; R, reverse; PCN, pregnenolone 16α-carbonitrile; PBP, peroxisome proliferator-activated receptor (PPAR)-binding protein; GRIP, glucocorticoid receptor-interacting protein; SMRT, silencing mediator of retinoid and thyroid receptors; NCoR, nuclear receptor corepressor; CHX, cycloheximide; WT, wild-type.
SX R Is a Novel Target of Vitamin K₂

degen ergous steroids and dietary and xenobiotic compounds (29, 32).

During our original screening experiments that led to the discovery of SX R as a steroid and xenobiotic sensor, we noted that vitamin K₂ could also activate SX R. This observation led us to consider the possibility that vitamin K₂ might act as a bona fide SX R ligand to mediate biological processes other than xenobiotic metabolism and Senear. Since vitamin K₂ was previously suspected to have a transcriptional regulatory function in addition to its role as an enzyme cofactor (37), we hypothesized that SX R might be the mediator of this activity. In this report, we demonstrate that vitamin K₂ transcriptionally activates SX R in a dose-dependent manner and binds directly to SX R in vitro and in vivo. SX R mRNA is expressed in osteosarcoma cell lines, and vitamin K₂ induced the expression of the prototypical SX R target gene CYP3A4 in these cells. Vitamin K₂ up-regulates the steady state mRNA levels for a panel of osteoblastic bone markers in the osteosarcoma cell lines HOS, MG-63, and Saos-2, demonstrating a mechanistic connection between vitamin K₂ and bone development. The known SX R activators rifampicin and hyperforin induce the same panel of bone markers as does vitamin K₂, further confirming a role for SX R in the regulation of these genes. Finally, we found that vitamin K₂ was able to induce bone markers in primary osteocytes isolated from wild-type murine calvaria but not in cells isolated from PX R knockout mice. From these data, we conclude that vitamin K₂ modulates the expression of osteoblastic bone markers through SX R and infer that vitamin K₂ activation of SX R could be an important factor favoring the deposition of bone over its resorption. Therefore, SX R is likely to be involved in the maintenance of bone homeostasis in addition to its known role in hormonal homeostasis. This reveals a novel biological function for SX R and suggests that a subset of SX R activators may function as effective therapeutic agents for the management of osteoporosis.

EXPERIMENTAL PROCEDURES

SX R Detection by RT-PCR—HOS, MG-63, Saos-2, L5180, and HeLa cells were cultured in phenol red-free DMEM supplemented with 10% resin charcoal-stripped FBS. Total RNA was isolated using Trizol reagent (Invitrogen). For RT-PCR analysis, 1 μg of total RNA was reverse transcribed using Superscript II reverse transcriptase according to the manufacturer-supplied protocol (Invitrogen). PCR was performed with the following primer set: forward primer, 5'-CAACCGGGAAAGAGTTGCAA-3'; reverse primer, 5'-CTGGTCTCTGAGTGGCAGAT-3'. PCR was carried out at 37 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 45 s.

Cell Culture and Transfection—COS-7 cells were cultured and transfected as described previously (38). Typically COS-7 cells were cultured in phenol red-free DMEM supplemented with 10% FBS. For transient transfection experiments, COS-7 cells were seeded into 96-well plates at a density of 5000 cells/well. The next day cells were transfected with either CMX-GAL-SXR or CMX-GAL4 (control) together with tk(MH100)-luc reporter (39) and CMX-β-galactosidase transfection control plasmids using standard calcium phosphate precipitation methodology. 22–24 h after transfection, the cells were washed twice with phosphate-buffered saline supplemented with 1 mM MgCl₂ or DMEM-ITLB (DMEM containing 5 μg/ml insulin, 5 μg/ml holotransferrin, 5 μg/ml selenium, 0.5% defined lipid mix (Invitrogen), 0.12% (w/v) delipidated bovine serum albumin (Sigma)) (40). Ligands were typically purchased from Sigma and BIOMOL Research Laboratories Inc., made freshly from powder in MeSO or as 0.1 mM stocks, diluted in MeSO to appropriate concentrations, and added to media with vigorous vortex mixing. Ligands were added in DMEM-ITLB, and the cells were incubated for an additional 24–48 h. The cells were lysed in situ, and extracts were prepared and assayed for β-galactosidase and luciferase activity as described previously (41). Reporter gene activity was normalized to the β-galactosidase transfection controls, and the results were expressed as normalized relative luciferase units per OD β-galac-

tosidase per minute to facilitate comparisons between plates. Fold induction was calculated relative to solvent controls. Each data point represents the average of triplicates ± S.E. The experiments were repeated three times with similar results.

For coactivator recruitment experiments, GALA-coactivator plasmids were generated by cloning the receptor interaction domains of human TIF2 (GenBank™ accession number NM_006540, amino acids 563–790), human SRC-1 (GenBank™ accession number U59302, amino acids 600–800), or human ACTR (GenBank™ accession number AF036892, amino acids 600–788) into pCMX-GAL4. The GALA-PBP construct was described previously (30). To construct herpesvirus VP16 activation domain fusion proteins, full-length SX R was PCR-amplified and ligated in-frame into pCDG-VP16 vector (25). All constructs were sequenced to verify that neither were introduced into the VP16 reading frame.

Ligand Binding Assays—N-terminal His₆-tagged human SX R ligand binding domain was expressed in Escherichia coli together with the SRC-1 receptor interaction domain essentially as described previously (28). Active protein was refolded from inclusion bodies solubilized in denaturation buffer (8 M guanidinium-HCl, 50 mM HEPES, pH 7.4, 0.2 M NaCl, 25 mM dithiothreitol, 1% (w/v) Triton X-100) by rapid 10-fold dilution into binding buffer (50 mM HEPES, pH 7.4, 1% sucrose, 0.2 M NaCl, 0.1 mM dithiothreitol, 0.1% (w/v) CHAPS) followed by dialysis overnight at 4 °C against binding buffer. Binding assays were performed by coating 96-well nickel chelate FlashPlates (PerkinElmer Life Sciences) with a 10-fold molar excess of protein for 1 h at 22 °C in bicarbonate buffer (50 mM HEPES, pH 7.4) after 1-h prewarming (50 mM HEPES, pH 7.4, 1% sucrose, 0.2 M NaCl, 0.1% CHAPS) bound protein was removed from the wells by washing four times with binding buffer. [H]HSR12183 (33) (Amersham Biosciences) was added to a final concentration of 50 nM in each well either alone or together with competitor ligands in binding buffer as indicated. Incubation was continued for 3 h at room temperature. Total counts were measured using a Topcount scintillation counter (Packard Instrument Co.). Counts remaining after the addition of 10 μM clotrimazole were taken as nonspecific background and subtracted from all wells (33). All assays were performed in triplicate and reproduced in independent experiments.

Alkaline Phosphatase (ALP) Activity Assay—ALP activity was measured as described previously (42). Briefly, cells were harvested by washing twice with phosphate-buffered saline, then collected with a cell scraper, and transferred to 1.5-ml microcentrifuge tubes. Cell pellets were obtained by centrifugation at 14,000 rpm at 4 °C, and lysates were prepared with a solution containing 0.2% (w/v) Nonidet P-40 and 1 mM MgCl₂. Aliquots of lysate were combined with reaction buffer (1 mM diethanolamine, pH 9.8, 1.5 mM MgCl₂, and 10 μM p-nitrophenyl phosphate) and incubated at 37 °C for 30 min. Absorbance at 405 nm was measured using a Spectra MAX Plus spectrophotometer (Amersham Biosciences), and the enzyme activity was calculated as described previously (6). ALP activity was corrected for protein content, which was determined using the Bio-Rad protein assay kit.

Quantitative Real Time RT-PCR Analysis of Bone Biomarker Genes in Osteosarcoma Cell Lines—Human osteosarcoma cell lines HOS, MG-63, and Saos-2 were obtained from American Type Culture Collection (Manassas, VA) and cultured in phenol red-free DMEM supplemented with 10% resin charcoal-stripped FBS. Cells were treated with vitamin K₂, 1 μg/mL vitamin D₃, rifampicin, or solvent controls for 48 h. Total RNA was isolated and reverse transcribed as described above. Quantitative real time RT-PCR (QRT-PCR) was performed using the following primer sets: ALP (F, 5'-CATGGCGTTGGGGGCCAGAGGA-3'; R, 5'-CTAGCCCTCTAAGTGGTGGCACA-3'), osteopontin (F, 5'-CAGGAGGAGCATACCTCTA-3'; R, 5'-TGGCTGTGGGGTTTACCA-3'), matrix Gla protein (MGp; F, 5'-TGTACCTAAGGAAGGCCGA-3'; R, 5'-TCTGTGCTTTGCCAGCACCCATGCC-3'), osteocalcin (OC; F, 5'-CCTCTCTACAGGGCTTTGTTGTG-3'; R, 5'-TATCTCAAGGATGCCGTTCT-3'), glyceraldehyde-3-phosphate dehydrogenase (GAPDH; F, 5'-TGGACCTATGAGGCCCACA-3'; R, 5'-TCAAGGCTTTCACTATGGCACA-3'), CYP3A4 (F, 5'-GGTTTTCCATCAAGGGCTTTA-3'; R, 5'-TTCCCATCCATCGTGTGTTG-3'), and the SYBR green PCR master mix (BioRad, Hercules, CA). Real-time PCR was performed using a LightCycler (Roche Diagnostics) and SYBR Green I Fluorescence Detection System (MJ Research). All samples were quantitated with the comparative cycle threshold Ct method for relative quantitation of gene expression, normalized to glyceraldehyde-3-phosphate dehydrogenase (43).

Expression of Calvaria, Culture of Primary Bone Cells, and QRT-PCR—Calvaria were isolated from newborn wild-type and PX R knockout mice (postnatal day 1–5) and were digested sequentially with 0.1% collagenase, 0.05% trypsin, 4 mM EDTA in 1× phosphate-buffered saline essentially as described in Refs. 44 and 45. Bone cells released upon digestion were cultured in phenol-red free DMEM, 10% FBS and

B. Blumberg, unpublished observations.
SXR Is a Novel Target of Vitamin \( K_2 \)

**RESULTS**

**SXR Is Expressed in Osteosarcoma Cell Lines**—SXR functions as a xenobiotic sensor and is expressed at high levels in the liver and intestine where it modulates the levels of CYP enzymes and ATP-binding cassette family transporters (31, 46). SXR is expressed at lower levels in normal and neoplastic breast tissues (47) and breast cancer cell lines (MCF-7, T47D, MDA-MB-231, and MDA-MB-435) (47). It is not clear at present what role SXR is playing in other tissues. We were intrigued by the ability of vitamin \( K_2 \) to activate SXR in preliminary experiments. To ascertain whether vitamin \( K_2 \) might be mediating the effects of vitamin \( K_2 \), we first determined whether SXR was expressed in a panel of osteosarcoma cell lines using RT-PCR. SXR expression was observed in the LS180 human colon adenocarcinoma cells and in the osteosarcoma cell lines HOS, MG-63, and Saos-2. SXR mRNA was not detected in HeLa cells or in negative controls (Fig. 1). It has been previously reported that SXR is expressed in LS180 cells (28, 30), whereas it is not expressed in HeLa cells (48). SXR is expressed at higher levels in LS180 cells with lower levels in the osteosarcoma cell lines (Fig. 1).

**Vitamin \( K_2 \) Activates SXR**—SXR is activated by a diverse array of pharmaceutical agents including Taxol, rifampicin, SR12813, clotrimazole, phenobarbital, and hyperforin. As noted above, our early screening efforts aimed at identifying SXR ligands also demonstrated SXR activation by vitamin \( K_2 \). Accordingly we tested the ability of vitamin \( K_2 \) to activate SXR in dose-response experiments. As shown in Fig. 2A, vitamin \( K_2 \) activates CMX-GAL-SXR robustly with the highest levels of activation approximately equivalent to 1 \( \mu \)M rifampicin (RIF). In contrast, no activation was observed using CMX-GAL4 alone, demonstrating that the activation results from a specific interaction with the SXR ligand binding domain.

Next we tested the ability of vitamin \( K_2 \) to induce the SXR target gene CYP3A4 in cultured osteosarcoma cells. It has been reported previously that CYP3A4 expression is induced by RIF and vitamin \( D_3 \) in cultured HepG2 and LS180 cells (49, 50), although the 1\( \alpha,25-(OH)_2 \) vitamin \( D_3 \) induction of CYP3A4 is mediated by the vitamin \( D_3 \) receptor rather than by SXR (51). RIF induced the expression of CYP3A4 in all three lines (Fig. 2B). Vitamin \( K_2 \) was able to induce CYP3A4 expression at both 1 and 10 \( \mu \)M in all three lines. 1\( \alpha,25-(OH)_2 \) vitamin \( D_3 \) could not induce CYP3A4 expression in Saos-2 or HOS cells (Fig. 2B).

**Vitamin \( K_2 \) Specifically Binds to SXR in Vitro and in Vivo**—Since vitamin \( K_2 \) activates SXR in transient transfections (Fig. 2A) and induces the expression of a prototypical SXR target gene in osteosarcoma cells (Fig. 2B), we next sought to determine whether vitamin \( K_2 \) binds to SXR. One important measure of ligand binding is the ability of a compound to induce a nuclear receptor to interact with coactivator proteins. Accordingly we conducted coactivator recruitment experiments that utilized VP16-SXR together with fusions between the GAL4 DNA binding domain and the receptor-interacting domains of...
the nuclear hormone receptor coactivators SRC-1, TIF2, ACTR, and PBP (30). As shown in Fig. 3A, VP16-SXR was able to interact with PBP, SRC-1, and ACTR in the presence of vitamin K2 or the known SXR ligand RIF. The results from the coactivator recruitment experiments paralleled those of the activation assays. As is the case for other SXR ligands (30), vitamin K2 and RIF preferentially induced interaction between SXR and PBP or SRC-1 while producing weaker but detectable action domains of the indicated nuclear receptor coactivators. Cells were cotransfected with 1 and 10 μM RIF or vitamin K2. Values represent the average of triplicates ± S.E. Experiments were repeated twice with similar results. B, vitamin K2 specifically binds to the purified SXR ligand binding domain. His6-SXR ligand binding domain was coexpressed with the SRC-1 receptor interaction domain and purified. The receptor complex was bound to nickel chelate FlashPlates and incubated with 50 nM [3H]SR12813 (28,34) in the presence of the indicated compounds or solvent control. Values represent the average of triplicates ± S.E. and were replicated in independent experiments. Vit, vitamin; DEX, dexamethasone.

the nuclear hormone receptor coactivators SRC-1, TIF2, ACTR, and PBP (30). As shown in Fig. 3A, VP16-SXR was able to interact with PBP, SRC-1, and ACTR in the presence of vitamin K2 or the known SXR ligand RIF. The results from the coactivator recruitment experiments paralleled those of the activation assays. As is the case for other SXR ligands (30), vitamin K2 and RIF preferentially induced interaction between SXR and PBP or SRC-1 while producing weaker but detectable interactions between SXR and TIF2 or ACTR (Fig. 3A). We infer that vitamin K2 promotes association between SXR and nuclear receptor coactivators SRC-1 and PBP as would be expected from an authentic SXR ligand.

We next tested whether vitamin K2 binds to purified SXR protein in vitro using a sensitive scintillation proximity ligand binding assay similar to that used by other investigators (28,33). This assay used [3H]SR12813 and recombinant His6-tagged SXR coexpressed with the SRC-1 receptor-interacting domain (28) and nickel chelate FlashPlates (PerkinElmer Life Sciences). SR12813 interacts specifically with SXR with a dissociation constant of 40 nM (33). As seen in Fig. 3B, vitamin K2 and RIF are able to displace [3H]SR12813 from the SXR ligand binding domain, whereas the control compounds PCN and dexamethasone did not compete effectively for receptor binding. The Ki for vitamin K2 binding to SXR was determined to be 5.1 μM, a value in the range of other known SXR ligands (28,34). We infer from these results that vitamin K2 specifically binds to SXR in vitro and in vivo and conclude that it acts as a bona fide ligand for this receptor.

Effects of Vitamin K2, Rifampicin, and Hyperforin on Bone Biomarker Genes in Osteosarcoma Cell Lines—Vitamin K2 is used as a therapeutic agent to treat osteoporosis in Japan and is thought to act by stimulating the deposition of bone (6,7) and decreasing bone resorption (8–13), although the mechanism of action remained unclear before our experiments. We tested the effect of vitamin K2 and 1α,25-(OH)2 vitamin D3, two known therapeutic agents, on the expression of a panel of osteoblast marker genes in the human osteosarcoma cell lines HOS, MG-63, and Saos-2 and compared these with the effects of the SXR activators RIF and hyperforin in the same cells. We chose 1α,25-(OH)2 vitamin D3 as a positive control compound in this study because it is also used therapeutically to treat osteoporosis and is known to transcriptionally regulate a range of biological processes, including bone growth, bone remodeling, and the expression of osteoblastic markers such as ALP (52–54), osteocalcin (55), and OPN (56,57).

ALP is a widely distributed glycosylated membrane-bound ectoenzyme. Bone ALP is located on the surface of osteoblasts and is thought to play a major role in bone formation and mineralization (58,59). ALP levels are considered to reflect osteoblastic activity and can therefore be used as a biochemical marker for assessing metabolic bone disease, including bone metastasis (60). As seen in Fig. 4A, 1α,25-(OH)2 vitamin D3 treatment increased ALP activity 1.7-fold in HOS and Saos-2 cells and 4.0-fold in MG-63 cells. Vitamin K2 treatment led to a dose-dependent 1.4–2.0-fold increase in ALP levels in these cells, and RIF completely paralleled this effect (Fig. 4A). As will be seen with other markers below, there are notable differences in the response of particular cell lines to treatment with vitamin K2 or 1α,25-(OH)2 vitamin D3. For example, 1α,25-(OH)2 vitamin D3 is particularly effective at inducing ALP enzyme activity in MG-63 cells (Fig. 4A). The effect of vitamin K2 treatment on ALP enzyme in HOS cells is in agreement with other reports (6).

Consistent with the effects on ALP enzyme, QRT-PCR analysis showed that ALP mRNA expression levels were significantly increased by vitamin K2 and 1α,25-(OH)2 vitamin D3 in a dose-dependent manner in all three cell lines with 1α,25-(OH)2 vitamin D3 being more potent (Fig. 4B). Statistically significant changes in ALP enzyme and mRNA levels were seen at vitamin K2 concentrations of as little as 1 μM (Fig. 4, A and B), which is similar to therapeutic levels at which vitamin K2 is used clinically. RIF and hyperforin produced effects very similar to vitamin K2 (Fig. 4B). The concordance between ALP protein levels (Fig. 4A) and ALP mRNA levels (Fig. 4B) suggests that QRT-PCR analysis of marker gene expression will be predictive of osteoblastic activity in cultured osteosarcoma cell lines.

OPN is one of the major non-collagenous bone matrix proteins produced by osteoblasts (61,62). It is an early marker of osteoblast differentiation and a prominent component of the mineralized bone matrix that has been implicated in tissue mineralization and in the attachment of osteoclasts to the bone matrix. Vitamin K2 elicited a dose-dependent increase in OPN
FIG. 4. Effects of vitamin K₂ and rifampicin on osteoblastic marker genes in osteosarcoma cell lines. Human osteosarcoma cell lines HOS, MG-63, and Saos-2 were cultured in phenol red-free DMEM supplemented with 10% resin charcoal-stripped FBS in the presence or absence of ligands for 48 h. ALP activity and bone marker gene expression were determined by ALP activity assay and quantitative real time RT-PCR. Data from quantitative real time RT-PCR are shown as the mRNA expression levels of marker genes normalized to glyceraldehyde-3-phosphate dehydrogenase. A, ALP activity assay. B, ALP mRNA expression. C, OPN mRNA expression. D, MGP mRNA expression. E, OPG mRNA expression. Data from HOS (white bars), MG-63 (black bars), and Saos-2 cells (gray bars) is shown. Values represent the average of triplicates ± S.E. The experiments were repeated twice with similar results. Vit, vitamin.
expression with the 10 μM dose approaching the response observed with 1α,25-(OH)₂ vitamin D₃ (Fig. 4C). Rif and hyperforin again elicited nearly identical results to those of vitamin K₂ treatment (Fig. 4C).

MGP is a vitamin K-dependent extracellular matrix protein with a wide tissue distribution that is particularly abundant in bone and cartilage. MGP is thought to play a key role in the inhibition of tissue calcification (63, 64). 1α,25-(OH)₂ vitamin D₃ treatment was previously reported to increase both the level of MGP mRNA expression and the rate of MGP secretion into culture medium in osteosarcoma cells (65). We found that MGP mRNA levels were up-regulated by vitamin K₂, Rif, hyperforin, and 1α,25-(OH)₂ vitamin D₃ treatment (Fig. 4D). Unlike the other markers studied, MGP mRNA levels were only stimulated by the highest doses of vitamin K₂ and Rif used (10 μM) in MG-63 and Saos-2 cells.

OPG (also known as osteoclastogenesis-inhibitory factor) is a member of the tumor necrosis factor receptor family (66, 67). It is thought to function as a soluble decoy receptor activator of nuclear factor-κB ligand (RANKL). Recombinant OPG has been shown to block osteoclastogenesis in vitro and to increase bone density in vivo (68). 1α,25-(OH)₂ vitamin D₃ (10⁻⁷ M) increased OPG mRNA levels by 90 and 50% in a fetal osteoblastic cell line (hFOB) and normal trabecular osteoblastic cells (hOB), respectively (69). OPG mRNA levels were up-regulated by both low and high doses of vitamin K₂ as well as by 1α,25-(OH)₂ vitamin D₃ and hyperforin (Fig. 4E). Rifampicin was an effective inducer of OPG mRNA in all three cell lines, particularly HOS cells (Fig. 4E), confirming and extending the published results. In summary, three structurally different human SXR activators, Rif, hyperforin, and vitamin K₂, induce osteoblast bone markers in three different osteosarcoma cell lines supporting a role for SXR in regulation of some osteoblastic bone markers.

We next asked whether the effects of vitamin K₂ or Rif on the expression of the bone markers above were direct transcriptional effects. We first tested induction of the known SXR target gene CYP3A4 with 10 μM rifampicin at time points from 6 to 48 h. There was very little induction of CYP3A4 detected before 24 h after treatment in the positive control LS180 cells or in any of the osteosarcoma cells (Fig. 5). Therefore, the osteosarcoma cell lines were treated with vitamin K₂, Rif, or vitamin D₃ in the presence or absence of the protein synthesis inhibitor cycloheximide (CHX) for 24 h, and RNA was analyzed by QRT-PCR using primers for OPN, MGP, and CYP3A4. As shown in Fig. 6, the expression of both MGP and CYP3A4 induced by vitamin K₂ and Rif was not decreased by the presence of CHX in either the MG-63 or Saos-2 cell lines. CHX has been demonstrated to increase the stability of a number of mRNAs, explaining the increased expression of MGP and CYP3A4 seen in the presence of CHX. In contrast, the induction of OPN expression by vitamin K₂ and Rif was eliminated in the presence of CHX. No induction of osteoblast marker genes was seen at 6 or 12 h of treatment (data not shown), and no induction of ALP or OPG could be detected even after 24 h of treatment. These results indicate that CYP3A4 and MGP are direct transcriptional targets of activated SXR but that OPN requires ongoing protein synthesis for induction by vitamin K₂ or Rif.

Vitamin K₂ Induction of Bone Marker Genes Requires SXR—The data presented above provide strong evidence that the stimulation of osteoblast bone markers by vitamin K₂ occurs via direct transcriptional activation of SXR. To confirm that these effects were indeed mediated by SXR, we utilized primary bone cell cultures derived from collagenase/trypsin-digested calvaria isolated from wild-type (WT) and PXR knockout mice. Previous studies have shown that the cells isolated from calvaria by this method are primarily osteoblasts (45). PXR is the rodent homolog of human SXR, and the PXR knockout mouse has been used to demonstrate the key role SXR/PXR plays in the control of xenobiotic metabolism (29, 32). WT or PXR knockout cells were treated for 48 h with vitamin K₂, the rodent PXR activator PCN, or vehicle only. Total RNA was then isolated and analyzed using QRT-PCR with primers specific for mouse MGP and OPG. As shown in Fig. 7, vitamin K₂ and PCN were able to induce MGP and OPG expression in WT cells; however, the ability to induce either MGP or OPG was lost in the PXR knockout cells. Therefore, vitamin K₂ induction of osteoblast marker genes requires the expression of PXR/SXR in bone cells.

**DISCUSSION**

The regulation of bone mass in mammals is a complex process that requires a balance between the bone-forming cells (osteoblasts) and bone-resorbing cells (osteoclasts) (70). Vitamin K₂ plays several important roles in bone metabolism. Similar to its role in promoting blood clotting, vitamin K₂ is an essential cofactor for γ-carboxylase, an enzyme that catalyzes the conversion of specific glutamic acid residues to Gla residues. Vitamin K₂ is required for γ-carboxylation of bone matrix Gla-containing proteins such as MGP and osteocalcin. Incomplete γ-carboxylation of osteocalcin and MGP resulting from vitamin K deficiency is associated with osteoporosis and increased risk of fracture (15, 16). In addition to its function as an enzymatic cofactor, vitamin K₂ has a dual role in mediating bone homeostasis. It acts in an anabolic manner to stimulate the synthesis of osteoblastic markers and deposition of bone (6, 7). Vitamin K₂ decreases bone resorption by inhibiting the formation of osteoclasts (10) as well as their bone resorptive activity (11, 12). Vitamin K₂ treatment also induces apoptosis of osteoclasts (13) while inhibiting apoptosis of osteoblasts (71) thereby shifting the balance toward bone formation. Vitamin K₂ was also shown to enhance the induction of osteocalcin mRNA levels mediated by co-administered 1α,25-(OH)₂ vitamin D₃ (7, 37). The function of vitamin K₂ was previously only well understood as an enzymatic cofactor.

SXR is expressed at high levels in the liver and intestine where it acts as a xenobiotic sensor that regulates the expression of cytochrome P-450 enzymes such as CYP3A4 and CYP2C8 and ATP-binding cassette family transporters such as MDR1 and MRP2 (28, 30). SXR is thus a master regulator of xenobiotic clearance, coordinately controlling steroid and xeno-
biotic metabolism (31, 46). SXR is also expressed at lower levels in other tissues such as normal and neoplastic breast tissue (47), although no function has yet been described for SXR in these tissues. There are no data available about the expression of SXR in normal human bone; however, its mouse ortholog PXR is abundantly expressed in bone as measured by in situ hybridization (26). Our observation that vitamin K2 activated SXR-dependent reporter gene constructs led us to hypothesize that vitamin K2 could regulate the transcription of bone markers through activation of SXR.

In support of this hypothesis, we demonstrated that SXR is expressed in three well studied osteosarcoma cell lines, HOS, MG-63, and Saos-2 (Fig. 1). These cell lines are considered to be osteoblastic in nature and are commonly used as models for osteoblast formation (6, 72, 73). Vitamin K2 activated SXR-dependent reporter gene constructs led us to hypothesize that vitamin K2 could regulate the transcription of bone markers through activation of SXR.

In support of this hypothesis, we demonstrated that SXR is expressed in three well studied osteosarcoma cell lines, HOS, MG-63, and Saos-2 (Fig. 1). These cell lines are considered to be osteoblastic in nature and are commonly used as models for osteoblast formation (6, 72, 73). Vitamin K2 activated SXR-dependent reporter gene constructs led us to hypothesize that vitamin K2 could regulate the transcription of bone markers through activation of SXR.

Fig. 6. Vitamin K2 has direct transcriptional effects on MGP and CYP3A4 but not OPN. Either MG-63 (A) or Saos-2 cells (B) were pretreated with 10 μg/ml cycloheximide for 30 min prior to addition of 10 μM vitamin K2, 10 μM rifampicin, 10 nM vitamin D3, or vehicle only. Total RNA was harvested 24 h later, reverse transcribed, and analyzed by QRT-PCR using primers for OPN, MGP, and CYP3A4. Values represent the average of triplicates ± S.E. Vit, vitamin.

As described above, prior to this study a growing body of evidence existed linking vitamin K2 to positive effects on the formation of bone and protection against fractures. Although its role as an enzymatic cofactor that favors the formation of Gla residues is undoubtedly critical for bone development, the anabolic effects of vitamin K2 on osteoblasts, vitamin K2-mediated inhibition of osteoclast function, induction of osteoclast apoptosis, and inhibition of osteoblast apoptosis suggest a
SXR Is a Novel Target of Vitamin K₂

2. Seeman, E., Tsalamandris, C., Formica, C., Hopper, J. L., and McKay, J. (1994) J. Bone Miner. Res. 9, 739–743
3. Torgerson, D. J., Campbell, M. K., Thomas, R. E., and Reid, D. M. (1996) J. Bone Miner. Res. 11, 283–287
4. Kibanski, A., Adams-Campbell, L., Brassard, T., Blair, S. N., Boden, S. D., Dickerson, K., Gifford, D. R., Glase, L., Goldberg, S. R., Hruska, K., Johnson, S. R., McCauley, L. K., and Russell, W. E. (2000) in NIH Consensus Statement, Vol. 17, pp. 1–14, National Institutes of Health, Office of the Director, Bethesda, MD
5. Bouckaert, J. T., and Saad, A. T. (1960) Nature 185, 849
6. Akebo, Y., Hosoi, T., Inoue, S., Negami, A., Mizuno, Y., Kaneki, N., Nakamura, T., Ouchi, Y., and Orimo, H. (1992) Biochem. Biophys. Res. Commun. 187, 814–820
7. Koshlukar, Y., Hoshi, K., Ishibashi, H., and Shiraki, M. (1996) Calcif. Tissue Int. 59, 466–473
8. Hall, J. G., Pauli, R. M., and Wilson, K. M. (1980) Am. J. Med. 68, 122–140
9. Hart, J. P., Shearer, M. J., Klenerman, L., Huijbens, A., Huijbens, S., Kawan, S., and Lecluyse, E. L. (2001) J. Clin. Endocrinol. Metab. 60, 1258–1259
10. Akiyama, Y., Kara, N., Tajima, T., Murota, S., and Morita, I. (1994) Eur. J. Pharmacol. 263, 181–184
11. Kara, K., Akiyama, Y., Nakamura, T., Murota, S., and Morita, I. (1995) Bone 16, 179–184
12. Kara, K., Akiyama, Y., Tajima, T., and Shiraki, M. (1995) J. Bone Miner. Res. 10, 538–542
13. Kameda, T., Miyazawa, K., Mori, Y., Yutaka, S., Shikawa, M., Nakamura, Y., Mano, H., Kameda, Y., Kameday, A., and Kumezawa, M. (1996) Biochem. Biophys. Res. Commun. 229, 515–519
14. Weber, P. (1997) Int. J. Vitam. Nutr. Res. 67, 350–356
15. Feskanich, D., Weber, P., Willett, W. C., Rockett, H., Bouth, S. L., and Colditz, G. A. (1999) Am. J. Clin. Nutr. 69, 74–79
16. Booth, S. L., Tucker, K. L., Chen, H., Hannan, M. T., Gagnon, D. R., Cupples, L. A., Wilson, P. W., Orlovskas, J., Schaefer, E. J., Dawson-Duhigus, B., and Kiel, D. P. (2000) Am. J. Clin. Nutr. 71, 1201–1208
17. Orimo, H., Shiraki, M., Fujita, T., Inoue, T., and Kushida, K. (1992) J. Bone Miner. Res. 7, 1212–1232
18. Iwamoto, I., Kochi, S., Naguchi, S., Murakami, M., Fujino, T., Douchi, T., and Nagata, Y. (1999) Maturita 31, 161–164
19. Shiraki, M., Shiraki, Y., Aoki, C., and Miura, M. (2000) J. Bone Miner. Res. 15, 515–521
20. Kaneko, M., Hedges, S. J., Hosi, T., Fujiwara, S., Lyons, A., Crean, S. J., Ishida, M., Nakagawa, M., Takechi, M., Sanou, Y., Mizuno, Y., Hoshino, S., Miyao, M., Inoue, S., Horiki, K., Shiraki, M., Ouchi, Y., and Orimo, H. (2001) Nature 11, 315–321
21. Shearer, M. J. (1995) Lancet 345, 229–234
22. Suttie, J. W. (1985) Annu. Rev. Biochem. 54, 459–477
23. Binkley, N. C., and Suttie, J. W. (1995) J. Nutr. 125, 1812–1821
24. Vermeer, C., Jie, K. S., and Knapen, M. H. (1995) Annu. Rev. Nutr. 15, 1–22
25. Blumberg, B. R., Kang, H., Bolado, J., Jr., Chen, H., Craig, A. G., Moreno, T. A., Umesono, K., Perlmann, T., De Robertis, E. M., and Evans, R. M. (1998) J. Biol. Chem. 273, 12435–12437
26. Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Jones, M. A., McKee, D. D., Oliver, B. M., Willson, T. M., Zetterstrom, R. H., Perlmann, T., and Lehmann, J. (1998) Cell 92, 73–82
27. Berthou, G., Heinrich, J., Svenningsen, K., Asman, M., Jendeberg, L., Sydow-Backman, M., Olsson, R., Postling, H., Blomquist, P., and Berkenstam, A. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12208–12213
28. Dussault, L., Lin, M., Hollister, K. W., E. S., Sydow, T. W., and Forman, B. M. (2001) J. Biol. Chem. 276, 33309–33312
29. Staudinger, J. L., Goodwin, B. S., Jones, A. H., Hawkins-Brown, D., MacKenzie, K. M., LaTour, A., Ku, S. D., Brown, K. B., Reinhard, J., Willson, T. M., Koller, B. H., and Kliewer, S. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 3639–3647
30. Synold, T. W., Dussault, I., and Forman, B. M. (2001) Nat. Med. 7, 584–590
31. Willson, T. M., and Kliewer, S. A. (2002) Nat. Rev. Drug Discov. 1, 259–266
32. Xie, W., Barwick, J. L., Downes, M., Blumberg, B., Simon, C. M., Nelson, M. C., Neuschwander-Tetri, B. A., Brint, E. M., Guewhi, P., and Evans, R. M. (2000) Nature 406, 435–439
33. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C., LeaChevy, E. L., Lambert, M. H., Willson, T. M., Kliewer, S. A., and Moore, J. T. (2000) Mol. Endocrinol. 14, 27–39
34. Moore, L. B., Parks, J. D., Jones, S. A., Bledsoe, R. K., Consler, T. G., Stimmel, J. B., Goodwin, B., Liddle, C., Blanchard, S. D., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000) J. Biol. Chem. 275, 15122–15127
35. Wentworth, J. M., Agostini, M., Love, J., Schwabe, J. W., and Chatterjee, V. K. (2000) J. Endocrinol. 166, R11–R16
36. Moore, L. B., Goodwin, B., Jones, A. S., Wisely, G. B., Serabji-Singh, C. J., Willson, T. M., Collins, J. L., and Kliewer, S. A. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7500–7502
37. Koshlukar, Y., and Hoshi, K. (1997) J. Bone Miner. Res. 12, 431–438
38. Grun, F., Venkatesan, R. N., Tabh, M. M., Cao, C. C., Hernami, D., and Blumberg, B. (2002) J. Biol. Chem. 277, 43691–43697
39. Forman, B. M., Umesono, K., Chen, J., and Evans, R. M. (1995) Cell 81, 441–450
40. Buck, J., Grun, F., Derguini, F., Chen, Y., Kimura, S., Noy, N., and Hammerling, U. (1993) J. Exp. Med. 178, 675–680
41. Blumberg, B., Sabagh, W., Jugulmen, H., Bolado, J. R., Ong, E. S., and Evans, R. M. (1998) Genes Dev. 12, 3195–3205
42. Anonymous (1974) Sound J. Clin. Lab. Investig. 33, 291–306
43. Livak, K. J., and Schmittgen, T. D. (2001) Methods 43, 427–432
44. Wong, G. L., and Cahn, D. V. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 3167–3171
45. Partridge, N. C., Alcorn, D., Michelangeli, V. P., Kemp, B. E., Ryan, G. B., and
Martin, T. J. (1981) *Endocrinology* **108**, 213–219
46. Xie, W., and Evans, R. M. (2001) *J. Biol. Chem.* **276**, 37739–37742
47. Dotzlaw, H., Leygue, E., Watson, P., and Murphy, L. C. (1999) *Clin. Cancer Res.* **5**, 2103–2107
48. Masuyama, H., Inoshita, H., Hiramatsu, Y., and Kudo, T. (2002) *Endocrinology* **143**, 55–61
49. Dotzlaw, H., Leygue, E., Watson, P., and Murphy, L. C. (1999) *Clin. Cancer Res.* **5**, 2103–2107
50. Sumida, A., Fukuen, S., Yamamoto, I., Matsuda, H., Naohara, M., and Azuma, J. (2000) *Biochem. Biophys. Res. Commun.* **267**, 756–760
51. Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K., Domoto, H., Evans, R. M., Haussler, M. R., and Mangelsdorf, D. J. (2002) *Science* **296**, 1313–1316
52. Majeska, R. J., and Rodan, G. A. (1982) *J. Biol. Chem.* **257**, 3362–3365
53. Manolagas, S. C., Burton, D. W., and Deftos, L. J. (1981) *J. Biol. Chem.* **256**, 7115–7117
54. Mulkins, M. A., Manolagas, S. C., Deftos, L. J., and Sussman, H. H. (1983) *J. Biol. Chem.* **258**, 6219–6225
55. Kerper, S. A., Scott, B. A., and Pike, J. W. (1989) *Proc. Natl. Acad. Sci. U. S. A.* **86**, 4455–4459
56. Noda, M., Vogel, R. L., Craig, A. M., Pruhl, J., DeLuca, H. F., and Denhardt, D. T. (1990) *Proc. Natl. Acad. Sci. U. S. A.* **87**, 9995–9999
57. Prince, C. W., and Butler, W. T. (1987) *Collagen Relat. Res.* **7**, 305–313
58. Sugawara, Y., Suzuki, K., Koshikawa, M., Ando, M., and Iida, J. (2002) *Jpn. J. Pharmacol.* **88**, 262–269
59. Sumida, A., Fukuen, S., Yamamoto, I., Matsuda, H., Naohara, M., and Azuma, J. (2000) *Biochem. Biophys. Res. Commun.* **267**, 756–760
60. Luo, G., Ducy, P., McKee, M. D., Pinero, G.-J., Loyer, E., Behringer, R. R., and Karsenty, G. (1997) *Nature* **386**, 78–81
61. Price, P. A., Faus, S. A., and Williamson, M. K. (1998) *Arterioscler. Thromb. Vasc. Biol.* **18**, 1409–1407
62. Fraser, J. D., and Price, P. A. (1990) *Calcif. Tissue Int.* **46**, 270–279
63. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Lathy, R., Nguyen, H. Q., Woolen, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombier, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Patterson, W., Campbell, P., Boyle, W. J., et al. (1997) *Cell* **89**, 309–319
64. Zernik, J., Twarog, K., and Upholt, W. B. (1990) *Differentiation* **44**, 207–215
65. Tamada, T., Sone, T., Tomomitsu, T., Jo, Y., Tanaka, H., and Fukunaga, M. (2001) *J. Bone Miner. Metab.* **19**, 45–51
66. Reinholt, F. P., Hultenby, K., Oldberg, A., and Heinegard, D. (1990) *Proc. Natl. Acad. Sci. U. S. A.* **87**, 4473–4475
67. Fedde, K. N. (1992) *Bone Miner.* **17**, 145–151
68. Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., and Khosla, S. (1998) *Biochem. Biophys. Res. Commun.* **250**, 776–781
69. Uematsu, T., Nagashima, S., Niwa, M., Kohno, K., Sassa, T., Ishii, M., Tomono, Y., Yamato, C., and Kanamaru, M. (1996) *J. Lab. Clin. Med.* **136**, 181–193
70. Urayama, S., Kawakami, A., Nakashima, T., Tsuoi, M., Yamazaki, S., Hida, A., Ichinose, Y., Nakamura, H., Ejima, E., Aoyagi, T., Nakamura, T., Migita, K., Kawabe, Y., and Eguchi, K. (2000) *J. Lab. Clin. Med.* **136**, 181–193
71. Fedde, K. N. (1992) *Bone Miner.* **17**, 145–151
72. Fedde, K. N. (1992) *Bone Miner.* **17**, 145–151
73. Fedde, K. N. (1992) *Bone Miner.* **17**, 145–151
74. Rodan, G. A. (1998) *Proc. Natl. Acad. Sci. U. S. A.* **95**, 13361–13362
75. Urayama, S., Kawakami, A., Nakashima, T., Tsuoi, M., Yamazaki, S., Hida, A., Ichinose, Y., Nakamura, H., Ejima, E., Aoyagi, T., Nakamura, T., Migita, K., Kawabe, Y., and Eguchi, K. (2000) *J. Lab. Clin. Med.* **136**, 181–193
76. Fedde, K. N. (1992) *Bone Miner.* **17**, 145–151
77. Uematsu, T., Nagashima, S., Niwa, M., Kohno, K., Sassa, T., Ishii, M., Tomono, Y., Yamato, C., and Kanamaru, M. (1996) *J. Pharm. Sci.* **85**, 1012–1016
78. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
79. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
80. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
81. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
82. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
83. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514
84. Sano, Y., Tadano, K., Kaneko, K., Kikuchi, K., and Yuzuriha, T. (1995) *J. Nutr. Sci. Vitaminol. (Tokyo)* **41**, 491–514